Geron greenshoe fully exercised, augmenting stock sale to $62.1 million

By Jennifer Chiou

New York, Sept. 20 - Geron Corp. announced the underwriters exercised in full their 900,000-share greenshoe, raising the size of its follow-on stock offering by $8.1 million to $62.1 million.

Geron priced the offering of 6 million shares at $9.00 apiece after the market close on Sept. 15.

UBS Investment Bank is the bookrunning manager. SG Cowen & Co., LLC, Needham & Co. LLC, Lazard Capital Markets LLC, Rodman & Renshaw, LLC and WBB Securities, LLC are co-managers.

The Menlo Park, Calif., biopharmaceutical company develops anti-cancer therapies that target the enzyme telomerase.

It will use proceeds for research and development, including clinical trials for its drug candidates, and working capital as well as general corporate purposes.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.